Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.

International journal of cancer - 1 Feb 2022

Sefrioui David, Verdier Vincent, Savoye-Collet Céline, Beaussire Ludivine, Ghomadi Slim, Gangloff Alice, Goria Odile, Riachi Ghassan, Montialoux Hélène, Schwarz Lilian, Tuech Jean-Jacques, Frebourg Thierry, Michel Pierre, Sarafan-Vasseur Nasrin, Di Fiore Frédéric

Abstract excerpt

Transarterial chemoembolization (TACE) is used to treat patients with unresectable hepatocellular carcinoma (HCC). We evaluated the clinical impact of a-fetoprotein (AFP) and circulating cell-free and tumor DNA (cfDNA and ctDNA) changes around the TACE procedure. Our prospective monocentric study enrolled consecutive patients treated with TACE, with samples collected at baseline (D - 1), Day 2 (D + 2) and 1 month...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to alpha-Fetoproteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Hepatocellular

Share to Cell-Free Nucleic Acids

Share to Disease Progression

Share to DNA, Neoplasm

Share to Liver Neoplasms

Share to Telomerase

Source

Identifiers

PMID: 34622951
DOI: 10.1002/ijc.33829

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.PMID 34622951Read ↗

Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.Semantic proximity Read ↗

Multiple features of cell-free mtDNA for predicting transarterial chemoembolization response in hepatocellular carcinomaSemantic proximity Read ↗

Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.Semantic proximity Read ↗

Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular CarcinomaSemantic proximity Read ↗

Therapeutic efficacy of transarterial chemoembolization-radiofrequency ablation combination in hepatocellular carcinoma with a high tumor burdenSemantic proximity Read ↗

Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.Semantic proximity Read ↗

N6-methyladenosine reader YTHDC2 and eraser FTO may determine hepatocellular carcinoma prognoses after transarterial chemoembolization.Semantic proximity Read ↗

Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib.Semantic proximity Read ↗

Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinomaSemantic proximity Read ↗

GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.Semantic proximity Read ↗

Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α-FetoproteinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.